DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?

Zacks2024-12-19

DaVita, Inc. DVA has witnessed strong momentum year to date. Its shares have risen 40.1% compared with the industry’s growth of 11.5%. The S&P 500 composite has gained 27.7% in the same period. DaVita...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492757971?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644","is_english":true,"pubTime":"2024-12-19 20:42","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492757971","market":"us","top_or_hot":-1,"title":"DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?","media":"Zacks","content":"<div>\n<p>DaVita, Inc. DVA has witnessed strong momentum year to date. Its shares have risen 40.1% compared with the industry’s growth of 11.5%. The S&P 500 composite has gained 27.7% in the same period.\nDaVita...</p>\n\n<a href=\"https://finance.yahoo.com/news/davita-stock-gains-40-1-124200954.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/davita-stock-gains-40-1-124200954.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DaVita, Inc. DVA has witnessed strong momentum year to date. Its shares have risen 40.1% compared with the industry’s growth of 11.5%. The S&P 500 composite has gained 27.7% in the same period.\nDaVita...</p>\n\n<a href=\"https://finance.yahoo.com/news/davita-stock-gains-40-1-124200954.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0205194284.USD","symbol_name":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","start_time":0,"source_url":"https://finance.yahoo.com/news/davita-stock-gains-40-1-124200954.html","article_id":"2492757971","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492757971","pubTimestamp":1734612120,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"DaVita, Inc. DVA has witnessed strong momentum year to date. Its shares have risen 40.1% compared with theindustry’sgrowth of 11.5%. The S&P 500 composite has gained 27.7% in the same period.DaVita,carrying a Zacks Rank #3  at present, is witnessing an upward trend in its stock price, prompted by the company’s business model. The optimism, led by a decent third-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease . The company operates kidney dialysis centers and provides related medical services in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis , hospital inpatient dialysis and ancillary facilities such as ESRD laboratory and disease management services.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","MASI":"麦斯莫医疗","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","ARAY":"精确射线","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","BK4196":"保健护理服务","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4082":"医疗保健设备","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","AXGN":"AxoGen Inc.","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","DVA":"达维塔保健","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","BK4588":"碎股"},"translate_title":"DaVita股价今年迄今上涨40.1%：上涨背后的原因是什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1,"MASI":1,"ARAY":1,"DVA":0.9},"content_text":"DaVita, Inc. DVA has witnessed strong momentum year to date. Its shares have risen 40.1% compared with the industry’s growth of 11.5%. The S&P 500 composite has gained 27.7% in the same period.\nDaVita, carrying a Zacks Rank #3 (Hold) at present, is witnessing an upward trend in its stock price, prompted by the company’s business model. The optimism, led by a decent third-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.\nDaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (“ESRD”). The company operates kidney dialysis centers and provides related medical services in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis , hospital inpatient dialysis and ancillary facilities such as ESRD laboratory and disease management services.\nImage Source: Zacks Investment Research\nCatalysts Driving DaVita’s Growth\nThe rally of the stock price can be attributed to the strength of its dialysis and related lab services along with the company’s expansion into international markets. The optimism led by a solid third-quarter 2024 performance and robust business potential are expected to contribute further.\nDaVita is experiencing significant growth driven by its patient-centric care approach, leveraging the company’s kidney care services platform to offer a wide range of treatment models and modalities. The increasing prevalence of value-based partnerships in kidney health enables nephrologists, physicians and transplant programs to collaborate more effectively, enhancing the understanding of individual patient needs and facilitating improved care coordination and early interventions.\nA key element of DaVita’s growth strategy is the acquisition of dialysis centers and related businesses, as evident from the recent extension of its pilot phase for a supply and collaboration agreement with Nuwellis. In June 2024, Nuwellis announced the extension of its pilot phase under the company’s previously announced supply and collaboration agreement with DaVita until Aug. 31, 2024.\nDaVita is also steadily expanding in the international markets which seems to interest investors. In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers. Currently, DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships.As of Sept. 30, 2024, DaVita provided dialysis services to around 265,400 patients at 3,113 outpatient dialysis centers, of which 2,660 were in U.S. centers while 453 were located across 13 other countries. During the third quarter of 2024, the company opened three dialysis centers in the United States. It also acquired one and opened four dialysis centers outside the United States in the same period.\nAs of Sept. 30, DaVita had approximately 69,500 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.4 billion in annualized medical spending. The company also had an additional 13,900 patients in other integrated care arrangements.\nFurthermore, DaVita has reiterated its earnings predictions for fiscal 2024, forecasting adjusted EPS in the range of $9.25 to $10.05, up from the prior band of $9-$9.80, which is likely to attract further interest from investors.\nDVA’s Risk Factor\nDaVita faces a risk of reduced profitability when patients shift from commercial insurance to government programs, as government reimbursement rates are significantly lower. This shift could be triggered by rising unemployment, impacting DaVita's revenues and profit margins.\nDVA’s Estimates\nThe Zacks Consensus Estimate for DaVita’s 2024 and 2025 bottom line is expected to increase 14.6% and 15.7%, respectively, to $9.71 and $11.42 year over year.\nIn the past 30 days, the Zacks Consensus Estimate for the company's 2024 earnings has remained constant.\nRevenues for 2024 and 2025 are anticipated to rise 5.5% and 3.7%, respectively, to $12.8 billion and $13.3 billion on a year-over-year basis.\nKey Picks\nSome better-ranked stocks in the broader medical space are Masimo MASI, Accuray ARAY and AxoGen AXGN.\nMasimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nMASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 49.4% compared with the industry’s 6.7% growth year to date.\nAccuray, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 1200% for 2025. Its earnings missed estimates in three of the trailing four quarters and met in one, delivering an average negative surprise of 141.97%.\nARAY’s shares have lost 32.2% against the industry’s 6.7% growth year to date.\nAxoGen, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 252% for 2025. It delivered a trailing four-quarter average earnings surprise of 91.11%.\nAXGN’s shares have risen 111% year to date compared with the industry’s 6.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAccuray Incorporated (ARAY) : Free Stock Analysis Report\nDaVita Inc. (DVA) : Free Stock Analysis Report\nMasimo Corporation (MASI) : Free Stock Analysis Report\nAxoGen, Inc. (AXGN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492757971"}